Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X. B., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., Koh, H. A., Grischke, E., Frenzel, M., Lin, Y., Barriga, S., Smith, I. C., Bourayou, N., Llombart-Cussac, A. AMER SOC CLINICAL ONCOLOGY. 2017
View details for DOI 10.1200/JCO.2017.35.15_suppl.1000
View details for Web of Science ID 000411895701137